Comparative Pharmacology
Head-to-head clinical analysis: ARGATROBAN versus DABIGATRAN ETEXILATE MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARGATROBAN versus DABIGATRAN ETEXILATE MESYLATE.
ARGATROBAN vs DABIGATRAN ETEXILATE MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, inhibiting fibrin formation, activation of coagulation factors V, VIII, XIII, and platelet aggregation.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, preventing fibrinogen cleavage and clot formation.
Initial dose: 2 mcg/kg/min IV continuous infusion; adjust to maintain aPTT 1.5-3 times baseline. For patients with HIT undergoing PCI: initial bolus 350 mcg/kg IV, then 25 mcg/kg/min IV infusion.
150 mg orally twice daily
None Documented
None Documented
Terminal half-life 39-51 minutes (dose-dependent); clinical context: continuous IV infusion required for stable anticoagulation.
Clinical Note
moderateArgatroban + Benzydamine
"Argatroban may increase the anticoagulant activities of Benzydamine."
Clinical Note
moderateArgatroban + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Argatroban."
Clinical Note
moderateArgatroban + Droxicam
"Argatroban may increase the anticoagulant activities of Droxicam."
Clinical Note
moderateArgatroban + Loxoprofen
Terminal elimination half-life: 12–17 hours (mean ~14 hours) in healthy adults; prolonged to 15–34 hours in moderate renal impairment (CrCl 30–50 mL/min); no significant change in mild hepatic impairment. Clinical context: Supports twice-daily dosing; accumulation risk in renal impairment.
Primarily hepatic (CYP450) metabolism; fecal (~65% as unchanged and metabolites) and renal (~22% with ~16% unchanged) elimination.
Renal: 80% unchanged drug via glomerular filtration and tubular secretion; Fecal: ~6% via biliary secretion; Hepatic metabolism (minor) via esterase-mediated hydrolysis to glucuronide conjugates (less than 5% of dose).
Category C
Category C
Direct Thrombin Inhibitor
Direct Thrombin Inhibitor
"Argatroban may increase the anticoagulant activities of Loxoprofen."